Key result
MCP-1 induces a novel transcription factor, MCPIP, causing cardiomyocyte apoptosis and ventricular dysfunction, leading to heart failure in mice and showing elevated levels in human ischemic hearts.
Why the study?
Does MCP-1/MCPIP expression induce cardiomyocyte apoptosis and ventricular dysfunction in preclinical models and human hearts?
Does MCP-1/MCPIP expression induce cardiomyocyte apoptosis and ventricular dysfunction in preclinical models and human hearts?
The novel transcription factor MCPIP, induced by MCP-1, mediates cardiomyocyte apoptosis and heart failure, highlighting a potential therapeutic target for ischemic heart disease.
MCPIP may drive ischemic cardiomyopathy; leaves open therapeutic targeting pending human trials.
Monocyte chemoattractant protein-1 (MCP-1; CCL2)-mediated inflammation plays a critical role in the development of ischemic heart disease (IHD). However, the gene expression changes caused by signal transduction, triggered by MCP-1 binding to its receptor CCR2, and their possible role in the development of IHD are not understood. We present evidence that MCP-1 binding to CCR2 induces a novel transcription factor (MCP-induced protein [MCPIP]) that causes cell death. Gene microarray analysis showed that when expressed in hiuman embryonic kidney 293 cells, MCPIP induced apoptotic gene families before causing cell death. Mutagenesis studies showed that the structural features required for transcription factor-like activity were also required for causing cell death. Activation of caspase-3 was detected after MCPIP transfection and Z-VAD-fmk partially inhibited cell death. Cardiomyocyte-targeted expression of MCP-1 in mice caused death by heart failure at 6 months of age. MCPIP expression increased in parallel with the development of ventricular dysfunction. In situ hybridization showed the presence of MCPIP transcripts in the cardiomyocytes and immunohistochemistry showed that MCPIP was associated with the cardiomyocyte nuclei of apoptotic cardiomyocytes. CCR2 expression in cardiomyocytes increased with the development of IHD. MCPIP production induced by MCP-1 binding to CCR2 in the cardiomyocytes is probably involved in the development of IHD in this murine model. MCPIP transcript levels were much higher in the explanted human hearts with IHD than with nonischemic heart disease. These results provide a molecular insight into how chronic inflammation and exposure to MCP-1 contributes to heart failure and suggest that MCPIP could be a potential target for therapeutic intervention.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2006) studied Ischemic heart disease. MCP-1 and MCPIP expression was evaluated on Cardiomyocyte apoptosis and ventricular dysfunction. MCP-1 induces a novel transcription factor, MCPIP, causing cardiomyocyte apoptosis and ventricular dysfunction, leading to heart failure in mice and showing elevated levels in human ischemic hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: